A Study to Evaluate the Safety and Effectiveness of Rivaroxaban (Xarelto) for Prevention of Stroke and Systemic Embolism in Indian Patients With Non-valvular Atrial Fibrillation (NVAF)

Inclusion Criteria

• •Patient should be an adult female or male, ≥18 years of age;
• •Patient should be diagnosed with NVAF and initiated with rivaroxaban treatment for prevention of stroke or systemic embolism per investigator's routine treatment practice;
• •Patient should not have received rivaroxaban in the past;
• •Patient/patient's legally acceptable representative should be willing to provide written informed consent.